Profit before tax fell 19.6% to Rs 28.30 crore in Q3 FY21 over Q3 FY20. Tax expense fell 12.1% to Rs 7.74 crore in Q3 FY21 over Q3 FY20.
AstraZeneca Pharma India is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease.